Karyopharm Therapeutics (KPTI) Insider Trading & Ownership $3.86 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$3.95 +0.09 (+2.31%) As of 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Karyopharm Therapeutics (NASDAQ:KPTI) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage2.75%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)5Amount OfInsider Selling(Last 12 Months)$1.26 M Get KPTI Insider Trade Alerts Want to know when executives and insiders are buying or selling Karyopharm Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address KPTI Insider Buying and Selling by Quarter Remove Ads Karyopharm Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails10/4/2024Richard A PaulsonCEOSell240$13.20$3,168.00 8/6/2024Richard A PaulsonCEOSell240$13.95$3,348.00 7/30/2024Stuart PoultonEVPSell192$15.90$3,052.80 7/5/2024Richard A PaulsonCEOSell241$12.75$3,072.75 6/7/2024Deepika PakianathanDirectorSell15,436$14.25$219,963.00 6/5/2024Deepika PakianathanDirectorSell31,202$14.40$449,308.80 6/4/2024Michael MasonCFOSell43$14.85$638.55 6/4/2024Richard A PaulsonCEOSell239$14.85$3,549.15 6/3/2024Deepika PakianathanDirectorSell24,049$15.00$360,735.00 5/31/2024Deepika PakianathanDirectorSell13,626$14.25$194,170.50 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 5/6/2024Richard A PaulsonCEOSell238$16.95$4,034.10 4/22/2024Reshma RangwalaEVPSell452$17.55$7,932.60 4/4/2024Richard A PaulsonCEOSell237$19.35$4,585.95 (Data available from 1/1/2013 forward) KPTI Insider Trading Activity - Frequently Asked Questions Who is on Karyopharm Therapeutics's Insider Roster? The list of insiders at Karyopharm Therapeutics includes Deepika Pakianathan, Garen G Bohlin, Michael Mano, Michael Mason, Reshma Rangwala, Richard A Paulson, Sohanya Roshan Cheng, Stephen Mitchener, and Stuart Poulton. Learn more on insiders at KPTI. What percentage of Karyopharm Therapeutics stock is owned by insiders? 2.75% of Karyopharm Therapeutics stock is owned by insiders. Learn more on KPTI's insider holdings. Which Karyopharm Therapeutics insiders have been buying company stock? The following insider purchased KPTI shares in the last 24 months: Garen G Bohlin ($50,178.60). How much insider buying is happening at Karyopharm Therapeutics? Insiders have purchased a total of 2,742 KPTI shares in the last 24 months for a total of $50,178.60 bought. Which Karyopharm Therapeutics insiders have been selling company stock? The following insiders have sold KPTI shares in the last 24 months: Deepika Pakianathan ($1,224,177.30), Michael Mano ($25,016.10), Michael Mason ($52,219.50), Reshma Rangwala ($53,653.05), Richard A Paulson ($180,045.90), Sohanya Roshan Cheng ($14,155.80), and Stuart Poulton ($15,632.85). How much insider selling is happening at Karyopharm Therapeutics? Insiders have sold a total of 101,100 Karyopharm Therapeutics shares in the last 24 months for a total of $1,564,900.50 sold. Karyopharm Therapeutics Key ExecutivesMr. Richard A. Paulson M.B.A. (Age 57)President, CEO & Director Compensation: $1.43MMs. Sohanya Cheng M.B.A. (Age 41)Executive VP & Chief Commercial Officer Compensation: $742.95kMr. Stuart PoultonExecutive VP & Chief Development OfficerDr. Reshma Rangwala M.D. (Age 46)Ph.D., Executive VP, Chief Medical Officer & Head of Research Compensation: $777.32kDr. Mansoor Raza Mirza M.D. (Age 63)Clinical Consultant, Member of Scientific Advisory Board & Independent Director Compensation: $150kDr. Sharon Shacham M.B.A. (Age 54)Ph.D., Co-Founder & Chairman of Scientific Advisory Board Compensation: $1.4MMr. Cameron Peters (Age 64)Vice President of Finance, Assistant Treasurer & Principal Accounting Officer Ms. Elhan Webb C.F.A.Senior Vice President of Investor RelationsMr. Michael J. Mano J.D. (Age 47)Senior VP, General Counsel & Secretary Compensation: $625.08kMr. James Accumanno J.D.Chief Compliance Officer More Insider Trading Tools from MarketBeat Related Companies Greenwich LifeSciences Insider Buying Journey Medical Insider Buying Seres Therapeutics Insider Buying Alector Insider Buying Enanta Pharmaceuticals Insider Buying Lexeo Therapeutics Insider Buying Zentalis Pharmaceuticals Insider Buying C4 Therapeutics Insider Buying FitLife Brands Insider Buying Virios Therapeutics Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Casey’s General Stores Insider Buys Shares of This Must-Own StockNVIDIA Insiders Sell: This Is What It Means for the Market Top 3 Insider Stock Buys in March—Are They Still Good in April?Grocery Outlet Insider and Institutional Buyers Signal BottomSentinelOne Insider Selling? Why Investors Should Stay Bullish This page (NASDAQ:KPTI) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
